Alpheus has begun a multi-centre study focused on butterfly glioblastoma (GBM), Clinical Trials Arena reports. The trial's launch was reported on Friday, 9 October 2026.
Butterfly GBM refers to a form of glioblastoma, an aggressive brain cancer, in which the tumour spreads across the brain's hemispheres. The condition takes its name from the butterfly-like pattern this spread creates.
According to Clinical Trials Arena, the study will run across multiple sites, a design typically used to enrol patients more quickly and to test results across a broader population than a single hospital could provide.
The report did not include details on the number of sites involved, the patient population, the specific treatment being tested, or the trial's phase. Those specifics were not available in the material published by Clinical Trials Arena.
Glioblastoma research remains an active area, with butterfly GBM drawing attention because its pattern of spread makes it difficult to treat with approaches that target a single, contained tumour.
What to watch next: Further details on the trial's design, enrolment criteria and treatment candidate, should Alpheus or Clinical Trials Arena publish them.
